**Title:**

# Hope for Others: Research Results from the University of Pittsburgh Rapid Autopsy Program for Breast Cancer


**Authors**

Alexander CC Chang[1,5*], Marija Balic[1,5], Tanner Bartholow[1,4], Rohit Bhargava[1,4], Daniel D. Brown[1,7], Lauren Brown[1,5], Adam Brufsky[1,5], Ye Cao[1,5], Neil Carleton[1,5], Amanda M. Clark[1,4], Morgan Cody[1,5], Kai Ding[1,5], Christopher Deible[1,5], Ashuvinee Elangovan[1,5], Julia Foldi[1,5], Daniel Geisler[8], Christine Hodgdon[14], Naomi Howard, Zheqi Li[1,5], Jie Bin Liu[1,5], Oscar Lopez-Nunez[4,16], Sheeba John Mary[1,5], Olivia McGinn[1,5], Lori Miller[1], Kanako Mori[1,5], Geoffrey Pecar[1,5], Nolan Priedigkeit[17], Shannon Puhalla[1,5,10], Margaret Q. Rosenzweig[1,3], Partha Roy[1,9], Laura Savariau[1,5], Stephanie Walker[12,13], Hunter Waltermire[1,5], Abdalla M Wedn[1,2] Alan Wells[1,4], Megan E. Yates[1,5], Jennifer Xavier[1,5], Adrian V Lee[1,2,7#] and Steffi Oesterreich[1,2,3#]

[1]Womens Cancer Research Center, UPMC Hillman Cancer Center, Magee-Women Research Institute, [2]Department of Pharmacology and Chemical Biology, University of Pittsburgh, [3]School of Nursing, [4]Department of Pathology, [5]Department of Medicine, [6]Department of Human Genetics, [7]Institute of Precision Medicine, [8]Department of Radiology, UPMC, [9]School of Bioengineering, Pittsburgh PA, USA., [10] NSABP, [11]bcRAN, Pittsburgh PA, USA [12]MBC Alliance [13]LBBC, [14] GRASP, [15] Moffitt Cancer Center. [16] Cincinnati Children's Hospital Medical Center. [17] DFCI/Broad Institute of MIT and Harvard. Boston, MA, USA.

* Denotes first author

# Denotes senior author.

**All other authors are in alphabetical order**


**Conflict of Interest Statement**

The authors have no conflicts of interest related to this work. Author RB is a former consultant for GE Health (now ended), and current Speaker's Bureau member for AstraZeneca. Author AB is a current consultant for AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma, Myriad, Gilead, Bria-Cell, and receives research support from Agendia and AstraZeneca.

**Abstract**

Breast cancer affects 1/8 of women throughout their lifetimes, with 90% of cancer deaths being caused by metastasis. However, metastasis poses unique challenges to research, as complex changes in the microenvironment in different metastatic sites and difficulty obtaining tissue for study hinder the ability to examine in depth the changes that occur during metastasis. Rapid autopsy programs thus fill a unique need in advancing metastasis research. Here, we describe our protocol and processes for establishing and improving the US-based Hope for OTHERS (Our Tissue Helping Enhance Research and Science) program for organ donation in metastatic breast cancer. Our results reveal key logistical and protocol improvements that are uniquely beneficial to certain programs based on identifiable features, such as working closely with patient advocates, methods to rescue RNA quality in cases where tissue quality may degrade due to time delays, as well as guidelines and future expansions of our program with new research and novel research findings in patient outcomes, metastatic phylogeny, living model development and more.

**Statement of Significance**

Rapid autopsy programs are unique research settings with huge potential for studying metastatic cancer, however, they have complex research challenges. Our work provides a valuable resource in advancing this field of research.

52 **Introduction**

53 Breast cancer affects 1 in 8 women throughout their lifetimes[1], with survival at five years
54 averaging 31% for patients who have distant metastases[2]. Despite significant gains in breast
55 cancer research and improvements in treatment in recent years, including the advent of CDK4/6
56 inhibitors and novel HER2-antibody drug conjugates, much work still remains to be done[3]. The
57 most lethal mechanism of breast cancer is metastasis, which is responsible for the majority of
58 cancer deaths, and addressing this challenge remains a critical focus of ongoing research
59 efforts[4,5].

60 However, metastasis is uniquely challenging to study, as it involves a complex interplay
61 between genetic and epigenetic modifications related to immune and other environmental
62 factors that are not easily captured in the laboratory setting. Clinical samples are urgently
63 needed as mouse models and other laboratory techniques may not fully capture the complexity
64 of human genetics and disease[6]. However, many clinical tissues that are biopsied are not
65 routinely preserved for research purposes and provide a limited number of organs and sites that
66 may not capture the full picture of metastasis[7,8].

67 Autopsies thus provide crucial diversity in the tissues collected for research purposes, which
68 leads to a more explicit understanding of the pathways taken during cancer metastasis[7].
69 Specific advantages include access to metastatic lesions that are challenging to biopsy, such as
70 bone; access from normal tissues to study organ tropism as well as intra/inter-organ
71 heterogeneity; larger amounts of tissue for in-depth molecular study/model development; and
72 the collection of tissue after lines of therapy to study drug resistance – a major challenge in
73 breast cancer treatment[9].

74 The establishment of a tissue donation program at UPMC Magee Women's Hospital was driven
75 by patient requests within the Breast Cancer Program, a component of the NCI-designated
76 UPMC Hillman Cancer Center and the Magee Women's Hospital. Between 2008 and 2015, four
77 patients with metastatic breast cancer nearing the end of their lives expressed a desire to
78 contribute to scientific research through body donation[10]. While these initial requests were
79 accommodated, the process lacked structure and organization. The development of this
80 structured tissue donation program was motivated by the need to streamline the process,
81 maximize the scientific value of donated tissues, and fulfill the wishes of patients who sought to
82 contribute to the advancement of breast cancer research even after their passing.

83 The significant quantity and quality of tissue obtained from these autopsies, coupled with the
84 recognition that serial tissue collection throughout metastatic breast cancer progression
85 enhances the value of autopsy tissue, highlighted the need for a formalized and proactive tissue
86 procurement program. This initiative aimed to gather tissue samples throughout the illness and
87 to ensure efficient and timely tissue collection at death, thereby honoring the patients' desire to
88 leave a lasting impact on cancer research and, thus, on future patients suffering from the
89 disease through improved understanding of breast cancer evolution, heterogeneity, and
90 metastases.

91 At the program's inception, no cancer-specific tissue autopsy procurement programs existed
92 within our academic center. However, an existing rapid autopsy program for Idiopathic
93 Pulmonary Fibrosis (IPF) patients served as a valuable model[10]. This IPF program helped
94 identify crucial departments, personnel, and procedural workflows necessary for conducting
95 autopsies effectively[11], and other major logistical changes that need to be implemented. Hence,
96 a major re-design was implemented in 2018, leading not only to exponential increases in
97 consents and autopsies but also to increases in the quality and quantity of tissue collection and
98 research progress.

99 This study presents a detailed analysis of the development, implementation, and outcomes of
100 our rapid autopsy program, addressing logistical challenges and highlighting solutions. We
101 report on diverse causes of death in metastatic breast cancer and emphasize the importance of
102 systematic tissue collection, including the discovery of micro-metastases in grossly normal
103 organs. Methodological advances in tissue preservation, particularly fixed sequencing
104 technologies for RNA integrity in post-mortem samples, are discussed alongside the
105 development of patient-derived organoids (PDOs) and xenografts (PDXs). Novel findings, such
106 as the identification of an ESR1-ARNT2 fusion in metastatic samples from one patient,
107 demonstrate the program’s potential to uncover new molecular features of metastatic breast
108 cancer. Our experience provides valuable insights for improving rapid autopsy protocols and
109 advancing metastatic cancer research globally.[12]

## Results

### Overall logistics of the HfO program from consenting to tissue processing

Our process for the Hope for OTHERS (Our Tissue Helping Enhance Research and Science) Tissue Donation Program illustrated in Figure 1 begins with the patient learning about and consenting to the program, which can occur years to days before their passing. Previous research from our group has shown that many patients are willing to discuss autopsy, but care providers must initiate such conversations[13]. As of August 2024, our average time from consent to death is 14-15 months, with a range of 0 to 53 months and a median of 10 months (Figure S1). Upon consent, we integrate the collection of longitudinal samples such as blood, ascites, and biopsies throughout the patient's treatment journey flagging them in coordination with the clinical team and biobanking them where possible. These samples are logged and preserved via the Pitt Biospecimen Core, allowing for comprehensive temporal analysis of cancer progression.

As the patient's condition declines, pathology and lab teams are alerted and prepared for potential tissue collection. Upon the patient's death, the program enters a critical 3-7 hour window. The research coordinator is promptly informed and contacts a livery service to transport the body to the morgue. Simultaneously, pathology, radiology, and lab teams are notified about the impending autopsy. Once the body arrives at the morgue, we collect a post-mortem CT (computed tomography) scan.

The final phase, lasting 1.5-3 hours, involves the actual tissue collection. The autopsy begins, and the lab team works to preserve specimens using various methods. These include snap freezing, FFPE (Formalin-Fixed Paraffin-Embedded) preservation, cryopreservation, and the initiation of PDX (Patient-Derived Xenograft) and organoid development. Following collection, tumor samples are transported in batches to the lab for further processing.

As of August 2024, our program has consented 114 patients and completed 37 autopsies, averaging 5.5 autopsies per year since 2018. Our patients' clinical characteristics (Table 1) reflect the general population demographics with ER+, PR+, HER2- being the most common molecular subtype. NST (no special type) is more prevalent than ILC (invasive lobular carcinoma) which also roughly approximates the frequency of ILC vs NST in the general population (~15%) at 4/30 (~13%) patients (Table 1). Stages at diagnosis ranged from 1A to 4. Our patients are most frequently diagnosed in stage 2A.

Figure 2 presents a comprehensive timeline of treatments and outcomes for the 30 patients from the post-2018 autopsies [pre-2018 not included due to inconsistent data prior to the 2018 program re-design], each represented by a horizontal bar plotting their treatment and progression information, normalized by total duration from the patient's initial diagnosis to the time of death. The first five squares color-code the characteristics of the patient for primary tumor molecular subtype, race, gender, histological subtype, and stage at the time of diagnosis.

Lastly, the treatment timeline uses color-coded bars to represent different therapies, including hormonal therapy, chemotherapy, targeted therapies, immunotherapy, and various inhibitors and conjugates. Simultaneous therapies are defined by vertically stacking bars. Our data shows that most of our patients, with some exceptions, follow similar treatment lines for their disease subtype. Symbols on the bars represent treatment markers, with an increasing density of red triangles later in treatment reflecting an increase in the progression rates in late-stage disease.

**Patient advocates play a crucial role in improving perceptions of the program**

The development of rapid autopsy and organ donation programs for breast cancer research is a sensitive undertaking that requires careful consideration of ethical, emotional, and practical concerns. As we embarked on this initiative, it quickly became apparent that the perspectives of those most intimately affected by breast cancer—the patients themselves—were indispensable. Recognizing the delicate nature of discussions surrounding end-of-life care and post-mortem tissue donation, we realized that incorporating breast cancer advocates into our program was not just beneficial, but essential. These advocates, often breast cancer survivors and/or individuals with close ties to the breast cancer community, bring a unique and vital viewpoint to the table. Their involvement ensures that our approach remains patient-centered, addressing the concerns and honoring the wishes of those who might consider participating in such programs.

Hence, as an extension of our process, our group specifically incorporated a group of patient advocates with metastatic disease to represent patient voices on the leadership committee. This has led to several notable improvements, as discussed below.

This group coordinated a rebranding of our program to The Hope for OTHERS (Our Tissue Helping Enhance Research & Science; HfO) Tissue Donation Program. The new name was carefully chosen to reflect the altruistic nature of tissue donation and its critical role in advancing scientific understanding of breast cancer.

172 As part of this rebranding effort, we developed an independent, patient-focused website and
173 created new materials such as brochures and pamphlets (Figure 3a). These resources were
174 designed to provide clear, compassionate information about the program to potential
175 participants and their families.

176 Our patient advocates have become integral members of the team, participating in our larger
177 Hope for OTHERS meetings and holding additional meetings among themselves to discuss
178 program improvements and outreach strategies. Their involvement ensures that patient
179 perspectives are consistently represented in all aspects of the program. For example, we have
180 recently participated in a podcast raising awareness of our program, which has been
181 downloaded 330 times to date across 17 countries (Figure 3a).

182 To increase awareness and engage with the broader breast cancer community, our program's
183 patient advocates have been actively presenting and distributing our materials (Figure 3a) at
184 various regional and national conferences, such as the Metastatic Breast Cancer Research
185 Conference 2024, Living Beyond Breast Cancer 2024, as well as advocacy events such as the
186 2024 Komen Pittsburgh More Than Pink Walk (Figure 3b).

187 Working closely with the advocate team and collaborating with groups across the country, we
188 have seen a significant increase in interest in tissue donation for research purposes in
189 metastatic breast cancer. Improving the perception of the program and its goals through
190 frequent bidirectional interactions ensures that the patient perspective remains central to our
191 efforts, furthering our mission of advancing breast cancer research through the normalization of
192 patient donations.

193 **A clinical coordinator specifically dedicated to the HfO program assures communication**
194 **and increases program efficacy**

195 Rapid autopsy programs require engagement with numerous stakeholders, including but not
196 limited to multiple clinical and basic departments, patient advocates, patients' families, industry
197 collaborators, researchers, regulatory offices, and funding agencies. The multi-layered
198 complexities of the program require the commitment of and oversight by scientists who are truly
199 vested in the success of the program, for example, those with a research focus on metastatic
200 breast cancer, as is the case in our program.

201 An essential improvement of our program has been the addition of a dedicated clinical
202 coordinator. The clinical research coordinator is an integral part of the program, interacting with

care providers, patients, and their families, pathologists on call, livery service, and the lab specimen processing team (Figure 1). While factors such as travel time for patient transport are outside of the coordinators control, we are only able to keep a narrow and consistent autopsy and processing time due to coordinator communication between the research lab and the autopsy team (Figure 3c), as well as maintain a steady increase in rates of consents due to their integrated and dedicated role in the clinic (Figure 3d).

We have established a structured meeting schedule to maintain program flexibility and continuous improvement. Biweekly meetings with the active operational group focus on case discussions, areas for improvement, and research progress monitoring. Bimonthly meetings involving all multidisciplinary team members and major stakeholders allow for sharing results and discussing larger-scale improvements, such as annual reviews of our standard operating protocols. A major re-design of roles and responsibilities, in 2023, by shifting more research responsibilities to dedicated research and autopsy coordinators, led to a dramatic change in our rate of consents by the clinical coordinator due to a more focused and narrow scope as a result (P-value 6.38E-31) (Figure 3d).

**Comprehensive and Diverse Tissue Collection Enhances Longitudinal Metastatic Breast Cancer Research via Rapid Autopsy**

At autopsy, we currently prioritize three collection modalities:

1. FFPE cassettes
2. Snap-frozen tissue for molecular analyses
3. Cryopreserved tissue for the development of patient-derived organoids (PDOs) and patient-derived xenografts (PDX)

As of August 2024, we have collected a sum total of 1244 FFPE blocks, with a median of 41 per patient (range of 7 – 69) (Figure 4a).

We have also collected 511 unique frozen tumors, with a median of 12 per patient (range of 3-27) (Figure 4b). A key strength of our program is the ability to access the original primary tumor samples for 25 of our cases (64%), despite sometimes being decades between primary surgery and death. This, combined with intermediate samples such as liver biopsies from the clinic, creates unique opportunities for longitudinal studies examining the evolution of metastatic breast cancer. Lastly, we have also collected 1952 cryovials, with a median of 46 per patient, and a range of 0 to 142 (Figure 4c).

234 Our research strategy also prioritizes the longitudinal capture of patient data, which can then be
235 linked to future research studies; this includes both clinical data and, more importantly, liquid
236 biopsy blood collections at each progression. These collections are a result of close
237 coordination and collaboration with the medical oncology department and allow us to keep track
238 of patient status, treatment progression, and other important clinical notes that might otherwise
239 be missed and consolidate them for consistent formatting inclusive of the clinical context of each
240 progression. For our 37 cases, we have collected 90 total, with a median of 2 per patient and a
241 range of 1 to 8 progression blood collections (Figure 4d).

242 A primary improvement due to our autopsy process has been a noted increase in the diversity of
243 tissue collected compared to previous studies in metastatic tissue. Even in studies that
244 prospectively select for metastatic tissue, such as the 91 patients with metastatic breast cancer
245 in the MET500 study, biopsies for liver and lymph nodes are overwhelmingly the majority of
246 samples collected (61.9%)[14] due to ease of access in the clinical setting (Figure 4e). Our results
247 highlight the advantage of rapid autopsy programs to increase diversity of tissue samples
248 collected.

249 As of August 2024, our program has collected from 228 organ sites, with fairly equal
250 representation from many tissue sites, with liver (12.7%), lung (10.5%), and spleen (8.8%),
251 making the top three showing relatively similar levels of collection. Furthermore, we also show
252 increased diversity with rare sites of micro-metastases or local invasion such as thyroid,
253 bladder, and diaphragm also being collected. We have collected from 29 total unique tissues
254 compared to 11 (AURORA US Clinical Samples), 18 (MET500), and 11 (AURORA EU) from
255 programs that collect using clinical biopsies (Figure 4e)[7,14,15]. This emphasis on comprehensive
256 sampling via an autopsy approach has allowed us to capture a more complete picture of
257 metastatic progression and organ involvement. All tissues are kept in -80 or -150 freezers and in
258 duplicate both in our lab and at the Pitt Biospecimen Core to ensure backups in case of power
259 outage or other system failures.

260 **Differential causes of death in breast cancer necessitate consistent and diverse tissue**
261 **collection.**

262 Recent research has identified that causes of death in metastatic breast cancer are varied and
263 require further examination[16]. To investigate this, we conducted a systematic review of our
264 clinical records and autopsy reports after noting discrepancies between patient symptoms and

265 gross clinically detected metastases. We focused specifically on lab values and medical notes
266 from the last six months of life as well as the final autopsy report after death.

267 This analysis showed that the primary cause of death in the majority of patients enrolled in the
268 HfO program was liver failure or respiratory failure (Figure 5a). However, while the majority
269 (90%) of the liver failure pathologies were similar, with consistent signs of hyperbilirubinemia,
270 portal hypertension, and cardiac strain, lung pathologies were much more diverse in the
271 proximal cause, including but not limited to kidney failure, disseminated intravascular
272 coagulation, saddle pulmonary embolism, pneumonia, enhertu-related pneumonitis, and pleural
273 effusions. Some, such as saddle pulmonary embolisms, have known or hypothesized causes
274 currently under study[17]. Critically, many organ systems were revealed to have detrimental
275 effects on others, such as the liver on the kidney due to breakdown of blood supply, or how
276 respiratory failure or liver failure could each cause cardiac strain. This illustrates how
277 disentangling the specific cause of death in multisystem organ failure due to complications
278 associated with metastatic breast cancer is a challenging task. Our data shows that causes of
279 death in patients can vary in pathology and urgently demand further precise investigations into
280 the underlying biology.

281 Often, the differences in metastatic organs can be microscopic. A review of all grossly normal
282 organs from our patients showed that, on average, at least one additional organ from a patient
283 may have micro-metastases not visible on clinical imaging (Figure 5b).

284 These have important implications for the journey of metastases and systemic responses to
285 these metastases in different immune tissues. In some cases of ILC, patients were deemed to
286 have 'normal liver' on CT repeatedly up until death, necessitating orthogonal approaches such
287 as identification of lesions using ultrasound and MRI (magnetic resonance imaging); (Figure 5c,
288 5d) only to reveal at autopsy multiple metastatic lesions affecting the hepatic parenchyma
289 despite consistently 'normal' CTs (Figure 5e, 5f) – a finding consistent with current ILC research
290 and emphasizing the need for improved imaging as well as orthogonal methods of metastatic
291 validation in addition to imaging[18].

292 This kind of discrepancy was observed to be common in our patients with ILC, where numerous
293 peritoneal organs often have metastases that are not visible clinically, as seen in Figure 5g. As
294 a result, we made changes in our collection protocol (see Supplemental 1) that have resulted in
295 increased standardized collection of lung, liver, brain, and bone in patients with NST and
296 peritoneal organs and tissues in patients with ILC, with clear anatomical labels and records,

297 increasing data representation overall for these diseases (Figure 5h). In addition, the need and
298 desire to understand dormancy, especially in patients with late recurrences, such as in the case
299 of ILC[19], has prompted us to increase the collection of macroscopically normal tissue, such as
300 bone, lung, and spleen, as well as sites considered to be 'commonly' involved in cancer
301 metastasis – even if grossly normal (Figure 5i).

302 **Fixed single cell sequencing technologies are preferred for tissues with degraded RNA in**
303 **the autopsy context**

304 Previous research from Geukens et al. has shown that bulk RNA quality in tumor tissue
305 decreases rapidly within hours of time of death[20]. In order to explore this and extend this work,
306 we performed paired single nuclei sequencing from three liver samples using 3' chemistry from
307 frozen tissue that was snap frozen at autopsy, and using fixed flex technology from 10x
308 Genomics on matched fixed tissues that were fixed and paraffin embedded at autopsy. Fixed
309 flex uses multiple probes to identify fragments and multi-align probe signatures[21].

310 Our results showed significant degradation of RNA from frozen tissues, which is in line with
311 findings from previous research that RNA quality degrades in an autopsy setting[20]. At the same
312 targeting of 8000 cells, on average, 7920 cells (SD: 1115) pass quality control for fixed
313 sequencing, but only 6959 (SD: 585) pass quality control for frozen sequencing.

314 Additionally, fixed sequencing technologies can rescue some of the signals, resulting in an
315 increased number of genes detected. Fixed sequencing detects an average of 2408 genes
316 [95% CI 2387 - 2430] vs. 1454.77 [95% CI 1440.59 – 1468.95] in frozen sequencing. Fixed
317 sequencing also resulted in increased total molecular counts with an average of 3158.05 [95%
318 CI 3145.28 – 3170.81] total counts vs an average of 2357.83 [95% CI 2347.03 – 2368.63].

319 Lastly, we also see decreased mitochondrial contamination with an average of 0.65% mtDNA
320 percentage [95% CI 0.64 – 0.65] vs 0.92% [95%CI 0.91 – 0.94] (Figure 6a).

321 Here, we see that fixed technologies also reduced noise, as these samples integrate better in
322 the case of fixed technologies. They also show a wider variety of cellular populations with more
323 significantly increased heterogeneity (Figure 6b and Figure 6c) – crucially Figure 6b reveals that
324 even among samples processed together, degradation from the autopsy itself contributes to
325 significant divergence in UMAP clustering and that in frozen technologies these differences are
326 too large to be disentangled using Harmony, but are correctable in fixed sequencing in Figure

327 6c. We also see an increase in signal detection, as ESR1, and CD4 for example are higher
328 detected in Figure 6c when using fixed sequencing.

329 Downstream analysis is also impacted, in Figure 6D we integrate the samples and label by cell
330 type. For quality assessment, we exclude the cancer cells specifically, as inherent cancer
331 subclone heterogeneity and the expression of neuronal and stem-like markers common in
332 cancer cells are confounding factors in this analysis comparing sequencing techniques, as
333 single-cell sequencing analysis is unable to reliably deconvolute the number of subclones
334 present and how much of the variation is due to inherent cancer heterogeneity vs. technique
335 differences. We do not have such significant variations in the ground truth in other cell types
336 which allows us to more accurately assess quality of each sequencing technique. We then run
337 side by side pathway analysis on cell type populations identified in both groups and show
338 significant reduction in pathway activity detection in the Hallmark pathways.

339 While the same pathways are present in both fixed and frozen data in Figure S2, there is always
340 a decreased gene set percentage in frozen data and a decreased pathway score, indicating
341 worse signal quality (Figure S2).

342 **Time from death of patient to processing tissue is critical for developing living models**
343 **and reveals metastasis evolution.**

344 Through our HfO program, we have established additional corollaries for PDO and PDX
345 generation. Specifically, we have been successful in generating 14 PDOs from 7 patients, and 8
346 PDX from 4 patients, covering a range of molecular and histological subtypes.

347 Across 27 attempts with 13 successes at developing PDOs, logistic regression revealed time to
348 end of processing was a significant factor in organoid growth success, with the latest success in
349 our tests being at 9 hours (Figure 7a) and a coefficient of -0.0132 for each additional minute of
350 delay from time of death to end of processing ($p = 0.027$). We have also recently had significant
351 success with 4 cryopreserved PDO developments out of 5 attempts and are currently
352 accelerating new attempts from prior banked samples to unlock the potential of past collections
353 further.

354 We are also collaborating with Champions Oncology on the generation of PDX models, with 11
355 patients, 34 attempts, and 8 successes, with no successes past the 10-hour mark after the time
356 of death (Figure 7c). Lastly, logistic regression confirmed a commonly known factor in PDX

357 success in triple negative vs. ER+ tumors, with coefficient of -2.8194 and p-value of 0.017,
358 confirming prior findings that tumors that are ER+ have greater difficulty in engrafting[22].

359 Furthermore, our collaboration with Champions has led to the generation of a custom protocol
360 for excising tissue chunks for PDX implantation – noting that minced tissue is preferred for PDO
361 generation, but chunked whole tissue is preferred for PDX generation (Figure S3).

362 Hence, careful evaluation of the number of each type of tissue preservation is essential to
363 maximize downstream research options while operating with time constraints to transfer tissues
364 in media and/or on ice as fast as possible.

365 **Novel research findings and the importance of collaboration with external partners.**

366 These PDX models have also given us unique opportunities for the study of metastatic
367 progression. For example, we made the novel discovery of an *ESR1-ARNT2* fusion in a PDX
368 model (Figure 8a) generated from a sample from a patient who participated in the HfO program.
369 We then found the *ESR1-ARNT2* gene fusion to be ubiquitous among the metastatic tissues
370 collected from our program for that patient (Figure 8b). We were subsequently able to cultivate a
371 patient-derived xenograft organoid (PDXO) from this model (Figure 8c), and demonstrated that
372 both the PDX and PDXO expressed the *ESR1-ARNT2* fusion gene (Figure 8d). We were able
373 to express this fusion in cell-lines (Figure 8d), and are now studying it in greater detail. This then
374 helps us build on previously published work from our lab as well that of other labs demonstrating
375 that ESR1 fusions have unique activity and frequency in metastatic ER+ breast cancer tissue[23–
376 25].

377 The acceleration of our consent and autopsy progress has also been reflected in our research
378 efforts. As of August 2024, we now have multiple projects in progress, including but not limited
379 to research efforts looking at dormancy, genomic structural evolution, leptomeningeal
380 metastasis, expansion of PDX model development to look at specific drug resistance models,
381 ESR1 mutant effects in the liver microenvironment, and international collaborations at the
382 clinical and molecular history of changes in breast cancer subtypes such as ILC with the
383 UPTIDER program[20]. We expect critical discoveries in the coming years from the growing
384 number of autopsy programs including ours. It's important to note that the nature of these
385 programs is highly dependent on the rate of sample collection and quality of data collected for
386 research productivity and thus requires a certain degree of establishment before research
387 output can catch up, which we have only recently managed to reach. This kind of investment
388 requirement has significant funding and research planning implications.

## Discussion

The Hope for OTHERS (Our Tissue Helping Enhance Research and Science) Organ Donation Program represents a significant advancement in metastatic breast cancer research. Our experiences and findings underscore the critical importance of rapid autopsy programs in understanding the complexities of metastatic progression and treatment resistance, but also the challenges and complexities that require close and frequent communications of multidisciplinary teams, including patients and researchers that are truly vested in the program and therefore function as its champion. Hence, many programs face obstacles from the very beginning without first ensuring the necessary support and collaboration, as shown by the continued rarity of programs such as ours both nationwide and globally[12].

### Programmatic Improvements and Their Impact

The implementation of a dedicated clinical coordinator has proven to be a cornerstone of our program's success. This role has been instrumental in facilitating communication between multiple stakeholders, streamlining processes, and ultimately contributing to the increased number of consented patients and completed autopsies. The upward trend in program participation (Figure 3d) demonstrates the effectiveness of this approach, which could serve as a model for other institutions seeking to establish or improve their rapid autopsy programs.

Our collaboration with patient advocates has been transformative, leading to improved branding, enhanced communication materials, and increased public awareness and normalization of the program. This patient-centric approach has not only boosted program participation but also ensured that our research remains aligned with patient needs and perspectives. The success of this strategy underscores the importance of including patient voices in research design and implementation, particularly in sensitive areas such as post-mortem tissue donation.

### Challenges and Solutions in Program Logistics

The challenges we faced, particularly in transportation times (Figure 3c), highlight the need for flexible and adaptive protocols in rapid autopsy programs. Our experience suggests that factors such as population density can significantly impact time efficiency (Figure 3c). Institutions in areas with similar geographical or logistical challenges might benefit from our findings, potentially adapting their protocols to mitigate these issues.

The interdepartmental collaborations we've fostered, particularly with Pathology and Radiology, have been crucial in maintaining relatively short time-to-autopsy windows and enhancing the

420 quality of our data collection (Figure 3c). These partnerships demonstrate the importance of a
421 holistic, institution-wide approach to rapid autopsy programs.

422 **Scientific Insights and Methodological Advances**

423 Our findings regarding the diverse causes of death in metastatic breast cancer (Figure 5a)
424 underscore the complexity of the disease and the need for comprehensive tissue collection
425 protocols. The discovery of micro-metastases in grossly normal organs (Figure 5b) highlights
426 the importance of systematic sampling, even in apparently unaffected tissues. This approach
427 has particular relevance for specific subtypes like ILC, where peritoneal (and other) metastases
428 may be clinically occult (Figure 5g, 5h) and dormancy is a very critical yet unresolved issue.

429 Other improvements include rapid cooling of organs in medium to slow metabolic activity and
430 molecular degradation[20]; consistent collection of all major organs even if grossly normal;
431 prioritization of tissues of key research interest, such as the leptomeninges.

432 The development of subtype-specific collection protocols (Figure 5h) represents a significant
433 methodological advance. This tailored approach ensures more consistent and relevant tissue
434 collection, potentially leading to more robust and representative datasets for future studies.

435 Our exploration of RNA quality preservation techniques (Figure 6a-d) provides valuable insights
436 for researchers facing similar challenges with post-mortem tissue quality. The superior
437 performance of fixed sequencing technologies in preserving RNA integrity and cellular
438 heterogeneity information could inform future methodological choices in single-cell studies using
439 autopsy tissues. Fixed sequencing technologies clearly decrease signal loss, as signal
440 integration and removal of batch effects are much clearer in fixed analysis. We suspect that part
441 of the batch effect is from the continued RNA degradation during extraction and lysis of cells to
442 isolate single nuclei, while fixed RNA is more stable, and any FFPE artifacts are rescued by the
443 redundancies in probe signals. In situations where tissue quality may be subpar or RNA quality
444 is expected to be degraded due to autopsy-related factors, fixed sequencing technologies are
445 preferred in single-cell applications. Fixed sequencing technologies, however, are not perfect,
446 as we do note that certain signals, such as CD8, are not detectable in either set of analyses,
447 and there is still significant RNA degradation compared to fresh single-cell sequencing collected
448 in optimal conditions such as surgical resections[26].

449 The time-sensitive nature of PDO model generation from autopsy tissues (Figure 7a, Figure S3)
450 offers crucial guidance for researchers aiming to develop living models from rapid autopsy

451 programs. These findings can help optimize tissue processing protocols and set realistic
452 expectations for model development success rates. Important to note is the high variability in
453 PDX success even within the same patient, implying significant factors other than time in PDX
454 development and ER+ status that need to be further optimized. Work to establish the effect of
455 tissue type is currently ongoing. The range of successes within patients also indicates that
456 tissue quality based on blood supply, technique and other similar factors could significantly
457 impact the success of PDX generation (Figure 7c).

458 **Novel Findings and Future Directions**

459 The identification of the ESR1-ARNT2 fusion (Figure 8b) exemplifies the potential of rapid
460 autopsy programs to uncover novel molecular features of metastatic breast cancer. This finding,
461 along with our ongoing studies on ESR1 fusion functions, demonstrates how rapid autopsy
462 programs can drive forward our understanding of treatment resistance and metastatic
463 progression. Both models are valuable and available to collaborators for further research,
464 emphasizing the importance of models developed from programs like ours.

465 The diverse range of ongoing projects stemming from our program, including studies on
466 dormancy, leptomeningeal metastasis, and rare subtypes like ILC, showcases the broad impact
467 of comprehensive rapid autopsy programs on breast cancer research and the potential for new
468 discoveries previously unknown.

469 **Limitations and Future Considerations**

470 Despite our successes, we acknowledge several limitations. The single-institution nature of our
471 study may limit the generalizability of some findings. Specifically, inter-institutional variations in
472 protocol may also lead to differences in downstream research results[12]. Additionally, while we've
473 made strides in reducing time-to-autopsy, further improvements could enhance tissue quality
474 and model generation success rates.

475 Future directions for our program include expanding collaborations with other institutions to
476 increase sample diversity and validate our findings across different populations. We also aim to
477 refine our tissue collection and processing protocols further based on emerging technologies
478 and research priorities.

479 In conclusion, the Hope for OTHERS Tissue Donation Program demonstrates the profound
480 impact that well-designed rapid autopsy programs can have on advancing metastatic breast
481 cancer research. By sharing our experiences, challenges, and solutions, we hope to contribute

482 to the broader effort of improving rapid autopsy protocols, increase patient enrollment and
483 ultimately advancing our understanding of metastatic breast cancer biology.

484

| Clinical Characteristics | | |
|---|---|---|
| Primary Molecular Subtype | ER+/HER2- | 22 (59.4%) |
| | ER+/HER2+ | 6 (16.2%) |
| | ER-/HER2+ | 1 (2.7%) |
| | TNBC | 7 (18.9%) |
| Race | White | 35 (94.6%) |
| | Black | 2 (5.4%) |
| Gender | Female | 36 (97.3%) |
| | Male | 1 (2.7%) |
| Histological Subtype | NST | 33 (89.2%) |
| | ILC | 4 (10.8%) |
| Stage at Time of Diagnosis | I - II | 19 (51.4%) |
| | III | 9 (24.3%) |
| | IV | 4 (10.8%) |
| | Unknown | 5 (13.5%) |

485

486 **Table 1:** Clinical characteristics of the autopsies performed as of August 2024

487

488

489 **Methods**

490 All dates and statistics are as of a freeze date of August 1st, 2024.

491 **Operating Protocol**

492 Please see attached Supplemental 1.

493 **Frozen single nuclei extraction**

494 *Reagents and Buffers*

495 Nuclei isolation was performed using the following reagents: Trizma® Hydrochloride Solution
496 (1M, pH 7.4; Sigma T2194), Sodium Chloride Solution (5M; Sigma 59222C), Magnesium
497 Chloride Solution (1M; Sigma M1028), Nonidet™ P40 Substitute (Sigma 74385), Phosphate-
498 Buffered Saline (PBS) with 10% Bovine Albumin (Sigma SRE0036), and Protector RNase
499 Inhibitor (Sigma 3335399001).

500 Two buffers were prepared:

501 Lysis Buffer (TST): Composed of 1X ST buffer (10 mM Tris-HCl, 146 mM NaCl, 21 mM MgCl2,
502 1 mM CaCl2), 0.03% Tween 20, and 0.01% BSA.

503 Wash Buffer: Prepared with 1% BSA, 0.2 U/μL RNase Inhibitor in PBS.

504 All buffers were pre-chilled on ice or at 4°C before use.

505 Frozen tissue samples were minced on dry ice and transferred to 1.5 mL microcentrifuge tubes,
506 with a sample volume not exceeding 500 μL.

507 500 μL of chilled Lysis Buffer was added to each sample. Tissues were homogenized on ice
508 using a Dounce homogenizer (Fisher 12-141-363) with 10-20 strokes over a 5-minute period.

509 An additional 500 μL of Lysis Buffer was added, and samples were incubated on ice for the
510 remainder of the 5-minute period, with intermittent mixing.

511 Homogenates were filtered through a 70 μm-strainer mesh, and the flow-through was collected
512 in a polystyrene round-bottom FACS tube.

513 The filtrate was transferred to a 1.5 mL tube, and 500 μL of Wash Buffer was added. Samples
514 were centrifuged at 500 g for 5 minutes at 4°C.

515 The supernatant was carefully removed, and the pellet was resuspended in 500 µL of Wash
516 Buffer. This washing step was repeated once.

517 After the final wash, nuclei were resuspended in Wash Buffer and counted. The suspension was
518 adjusted to a final concentration of 1000 nuclei/µL.

519 If necessary, an additional filtration step using a 40 µm Flowmi filter was performed to remove
520 any remaining debris.

521 Samples were kept on ice and then sent to the Single Cell Sequencing Core at the University of
522 Pittsburgh, targeting 8,000 cells for downstream sequencing.

523 **Fixed single nuclei extraction**

524 For FFPE single nuclei extraction, we used a modified version of the snPATHO-seq protocol
525 provided to us by the lab of Luciano Martelotto[27].

526 *Reagents and Equipment*

527 Reagents included Ethanol (Decon Laboratories #2701), Xylene (Epredia, 6601), Nuclease-
528 Free water (Invitraogen, AM9938), 1x Phosphate Buffer Saline (Ca2+ and Mg2+ free) (Corning,
529 21-031-CV), Liberase TM (Millipore Sigma, 5401119001), RPMI1640 (Gibco ), 10% BSA (),TST
530 Buffer and Wash buffer (See above in Frozen Single Nuclei extraction). Equipment used
531 included a Thermomixer with adjustable shaking (Eppendorf) and a refrigerated centrifuge.

532 Nuclei Isolation Procedure

533 2-4 tissue sections (25 µm-thick) or punches were collected and stored at 4°C if not used
534 immediately.

535 Paraffin was removed by washing sections three times with 1 mL Xylene for 10 minutes each.
536 Samples were rehydrated through an ethanol gradient (100%, 70%, 50%, 30%) for 1 minute
537 each.

538 Samples were washed once with 1× PBS + 0.5 mM CaCl2.

539 Tissue digestion was performed in 1 mL RPMI1640 supplemented with Liberase TM (1 mg/mL),
540 for 60 minutes at 37°C with shaking at 800 rpm.

541 After digestion, 400 µL of TST Buffer was added, mixed, and centrifuged at 850 x g for 5
542 minutes at 4°C.

543 The pellet was resuspended in 250 µL TST buffer containing 2% BSA and 1 U/µL RNAse
544 Inhibitor, then homogenized using a Dounce homogenizer (10-20 strokes).

545 An additional 750 µL of the EZ Lysis buffer mixture was added, followed by further
546 disaggregation by pipetting up and down and incubation on ice for 5 minutes.

547 The sample was filtered through a 70 µm PluriStrainer and centrifuged at 850 x g for 5 minutes
548 at 4°C.

549 Nuclei were washed twice with wash buffer and resuspended in PBS 0.5x + 0.02% BSA, put on
550 ice and delivered to the Single Cell Sequencing Core or stored in cryopreservation (see below).

551 Samples were then processed for Chromium X run using Chromium Fix RNA Profiling (10x
552 Genomics) following the manufacturer's protocol.

553 For cryopreservation, samples were supplemented with Enhancer solution (10x Genomics) and
554 0,22um filtered 10% Glycerol provided by the Single Cell Sequencing Core, incubated on ice for
555 10 minutes, and stored at −80°C.

556 This method was optimized for the preparation of nuclei suspensions from formalin-fixed,
557 paraffin-embedded (FFPE) tissue samples for single-nucleus RNA sequencing applications.

558 **Patient Derived Xenograft Development**

559 Tumor chunks were excised from the organ, with a slice down the middle for increased media
560 perfusion. Samples were then shipped same day to Champion Oncology lab for implantation.
561 For cryopreserved tissue, chunks 0.5 cm cubed in size were excised and frozen in freezing
562 media (See Supplemental 1 for details). These were then shipped frozen to Champions
563 Oncology overnight when required.

564 **Organoid generation and culture**

565

566 Patient-derived organoids (PDOs) were generated from consented primary human breast
567 cancer tissue from the Pitt Biospecimen Core in accordance with Institutional Review Board
568 protocol STUDY22030183 by the Institute for Precision Medicine according to established
569 protocol (Sachs et al 2018), with the addition of β-estradiol to the medium. Briefly, tumors were
570 digested with collagenase (Sigma C9407) on a rotator, sheared, filtered, and embedded in
571 Cultrex RGF Basement Membrane Extract (R&D Systems™ 353301002) in 24-well non-treated

572 plates (Fisher 12-566-82). Media replaced every 2-3 days and PDOs passaged every 2-4
573 weeks.
574
575 **Organoid Growth Assay**
576 PDOs were dissociated using 0.25% trypsin, washed in Advanced DMEM/F12, seeded at
577 20,000 cells per well in 96-well round bottom plates (Corning 353227), and cultured in standard
578 growth media (250 ng/ml Recombinant Human R-Spondin-3, 5 nM Recombinant Human
579 Heregulin β-1, 5 ng/ml Recombinant Human KGF (FGF-7), 20 ng/ml Recombinant Human
580 FGF10, 5 ng/ml Recombinant Human EGF, 100 ng/ml Recombinant Human Noggin, 500 nM A
581 83-01, 5 mM Y-27632, 500 nM SB 202190, 1X B-27 Supplement, 1.25 mM N-Acetyl-L-cysteine,
582 5 mM Nicotinamide, 50 mg/ml Primocin, 10 mM HEPES, 1X GlutaMAX, 100 U/ml Antibiotic-
583 Antimycotic, and 1X Advanced DMEM).
584
585 **Computational methods**

586 Frozen single nuclei sequencing data were aligned using CellRanger 7.1.0 while Fixed Flex
587 single nuclei sequencing was aligned using Multiranger 7.1.0. Standard Seurat Recipe
588 Preprocessing was used and samples were then Harmony integrated for comparison. Celltype
589 assignments were done using GSEAPY CellMarker2024 followed by manual review.

590 **Data Access Statement**

591 All single-cell sequencing data will be made available on NCBI GEO at time of publication.

592 **Western Blot Methods**

593 Cellular protein lysates were harvested utilizing RIPA buffer (50mM Tris pH 7.4, 150mM NaCl,
594 1mM EDTA (Thermo Fisher Scientific #15-575-020), 0.5% Nonidet P-40 (Sigma Aldrich
595 #74385), 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1X HALT protease and
596 phosphatase cocktail (Thermo Fisher #78442). Samples were vortexed, probe sonicated for 15
597 seconds (20% amplitude, Ultrasonic Processor GEX130) and centrifuged at 14,000rpm at 4℃
598 for 15 minutes. Protein concentration was assessed using the Pierce Bicinchoninic acid (BCA)
599 protein assay (Thermo Fisher #23225). Unless otherwise stated, 50µg of each protein sample
600 was run on a 10% SDS-PAGE gel followed with a 90V transfer at 4℃ for 90 minutes to a PVDF
601 membrane (Millipore #IPFL00010). Membranes were blocked for one hour with Intercept PBS
602 blocking buffer (LiCor #927-40000) at room temperature with rocking. Antibody probing was
603 performed overnight at 4℃ with rocking: ER$\alpha$, clone 60C (Millipore #04-820,

604 RRID:AB_1587018); HA (C29F4) (Cell Signaling Technologies #3724, RRID:AB_1549585); $\beta$-
605 actin (Millipore Sigma #A5441, RRID:AB_ 476744). After removal of primary antibodies, blots
606 were wash with 1X PBSTween 20 (0.1%) for 15 minutes, three times. Secondary antibodies
607 were applied for a one-hour room temperature incubation (1:10,000; anti-mouse 680LT (LiCor
608 #925-68020); anti-rabbit 800CW (LiCor #925-32211)). Imaging of membranes was performed
609 on the LiCor Odyssey CLx Imaging system.

610 **Acknowledgements**

611 We would like to thank the patients and their family and friends who believe in the program, and
612 have contributed to it in many ways. We are forever grateful to those patients who consented to
613 participate in the program.

614 We would like to thank the UPMC Cancer Registry, especially Vonda Mazzarella. Special
615 thanks goes to many members of the Department of Pathology who have contributed to the
616 program.

617 The authors would like to thank the Institute for Precision Medicine (IPM), a partnership of the
618 University of Pittsburgh and UPMC, for providing the patient-derived breast cancer organoids
619 used in these studies. Single Cell Gene Expression Flex was performed in the University of
620 Pittsburgh Single Cell Core Facility (RRID:SCR_025110) and services and instruments used in
621 this project were graciously supported, in part, by the University of Pittsburgh, the Department of
622 Medicine.

623 We would like to acknowledge Champions Oncology as a partner for the development of PDX
624 models for our program and look forward to continued advancements in model development.

625 We would also like to thank other peer organ donation and rapid autopsy programs for their
626 collaboration and advice, and we look forward to a continued expansion in the global community
627 of such programs to advance cancer research.

628 **Ethics Statement**

629 All research involving human participants was conducted with informed consent obtained
630 according to the ethical guidelines of the University of Pittsburgh Institutional Review
631 Board under STUDY19060376.

632 **Funding Statement**

633 The HfO program has been supported by the Magee Womens Research Institute and
634 Foundation, and Susan G Komen Foundation. This project used the UPMC Hillman Cancer
635 Center and Tissue and Research Pathology/Pitt Biospecimen Core shared resource which is
636 supported in part by award P30CA047904.

Work performed in the Pitt Biospecimen Core (RRID:SCR_025229) and services and instruments used in this project were supported, in part, by the University of Pittsburgh, the Office of the Senior Vice Chancellor for Health Sciences.

This research was supported in part by the University of Pittsburgh Center for Research Computing through the resources provided. Specifically, this work used the HTC cluster, which is supported by NIH award number S10OD028483.

644 **References**


645 1. Breast Cancer Risk in American Women - NCI. December 17, 2020. Accessed August 2,
646 2024. https://www.cancer.gov/types/breast/risk-fact-sheet

647 2. Survival Rates for Breast Cancer. Accessed February 1, 2024.
648 https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-
649 diagnosis/breast-cancer-survival-rates.html

650 3. Najjar MK, Manore SG, Regua AT, Lo HW. Antibody-Drug Conjugates for the Treatment of
651 HER2-Positive Breast Cancer. *Genes*. 2022;13(11):2065. doi:10.3390/genes13112065

652 4. A Perspective on Cancer Cell Metastasis | Science. Accessed August 5, 2023.
653 https://www.science.org/doi/10.1126/science.1203543

654 5. Dillekås H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases?
655 *Cancer Med*. 2019;8(12):5574-5576. doi:10.1002/cam4.2474

656 6. Ren Q, Khoo WH, Corr AP, Phan TG, Croucher PI, Stewart SA. Gene expression predicts
657 dormant metastatic breast cancer cell phenotype. *Breast Cancer Res BCR*. 2022;24:10.
658 doi:10.1186/s13058-022-01503-5

659 7. Garcia-Recio S, Hinoue T, Wheeler GL, et al. Multiomics in primary and metastatic breast
660 tumors from the AURORA US network finds microenvironment and epigenetic drivers of
661 metastasis. *Nat Cancer*. 2023;4(1):128-147. doi:10.1038/s43018-022-00491-x

662 8. Duregon E, Schneider J, DeMarzo AM, Hooper JE. Rapid research autopsy is a stealthy but
663 growing contributor to cancer research. *Cancer*. 2019;125(17):2915-2919.
664 doi:10.1002/cncr.32184

665 9. Hooper JE. Rapid Autopsy Programs and Research Support: The Pre– and Post–COVID-19
666 Environments. *Ajsp*. 2021;26(2):100-107. doi:10.1097/PCR.0000000000000435

667 10. Rosenzweig M, Miller LA, Lee AV, et al. The Development and Implementation of an
668 Autopsy/ Tissue Donation for Breast Cancer Research. *New Bioeth Multidiscip J Biotechnol*
669 *Body*. 2021;27(4):349-361. doi:10.1080/20502877.2021.1993608

670 11. Lindell KO, Erlen JA, Kaminski N. Lessons from Our Patients: Development of a Warm
671 Autopsy Program. *PLOS Med*. 2006;3(7):e234. doi:10.1371/journal.pmed.0030234

672 12. Desmedt C, Carey LA. Global post-mortem tissue donation programmes to accelerate
673 cancer research. *Nat Rev Cancer*. 2024;24(5):289-290. doi:10.1038/s41568-024-00683-w

674 13. Achkar T, Wilson J, Simon J, Rosenzweig M, Puhalla S. Metastatic breast cancer
675 patients: attitudes toward tissue donation for rapid autopsy. *Breast Cancer Res Treat*.
676 2016;155(1):159-164. doi:10.1007/s10549-015-3664-0

677 14. Robinson DR, Wu YM, Lonigro RJ, et al. Integrative Clinical Genomics of Metastatic
678 Cancer. *Nature*. 2017;548(7667):297-303. doi:10.1038/nature23306

679 15. Aftimos P, Oliveira M, Irrthum A, et al. Genomic and Transcriptomic Analyses of Breast
680 Cancer Primaries and Matched Metastases in AURORA, the Breast International Group

681 (BIG) Molecular Screening Initiative. *Cancer Discov*. 2021;11(11):2796-2811.
682 doi:10.1158/2159-8290.CD-20-1647

683 16. Boire A, Burke K, Cox TR, et al. Why do patients with cancer die? *Nat Rev Cancer*.
684 2024;24(8):578-589. doi:10.1038/s41568-024-00708-4

685 17. Kirwan CC, Descamps T, Castle J. Circulating tumour cells and hypercoagulability: a
686 lethal relationship in metastatic breast cancer. *Clin Transl Oncol*. 2020;22(6):870-877.
687 doi:10.1007/s12094-019-02197-6

688 18. Pereslucha AM, Wenger DM, Morris MF, Aydi ZB. Invasive Lobular Carcinoma: A
689 Review of Imaging Modalities with Special Focus on Pathology Concordance. *Healthcare*.
690 2023;11(5):746. doi:10.3390/healthcare11050746

691 19. Oesterreich S, Pate L, Lee AV, et al. International survey on invasive lobular breast
692 cancer identifies priority research questions. *Npj Breast Cancer*. 2024;10(1):1-7.
693 doi:10.1038/s41523-024-00661-3

694 20. Geukens T, De Schepper M, Van Den Bogaert W, et al. Rapid autopsies to enhance
695 metastatic research: the UPTIDER post-mortem tissue donation program. *Npj Breast Cancer*.
696 2024;10(1):1-14. doi:10.1038/s41523-024-00637-3

697 21. Single Cell Gene Expression Flex. 10x Genomics. Accessed February 8, 2024.
698 https://www.10xgenomics.com/products/single-cell-gene-expression-flex

699 22. Petrosyan V, Dobrolecki LE, LaPlante EL, et al. Immunologically “cold” triple negative
700 breast cancers engraft at a higher rate in patient derived xenografts. *NPJ Breast Cancer*.
701 2022;8:104. doi:10.1038/s41523-022-00476-0

702 23. Hartmaier RJ, Trabucco SE, Priedigkeit N, et al. Recurrent hyperactive ESR1 fusion
703 proteins in endocrine therapy-resistant breast cancer. *Ann Oncol*. 2018;29(4):872-880.
704 doi:10.1093/annonc/mdy025

705 24. Lei JT, Shao J, Zhang J, et al. Functional Annotation of *ESR1* Gene Fusions in Estrogen
706 Receptor-Positive Breast Cancer. *Cell Rep*. 2018;24(6):1434-1444.e7.
707 doi:10.1016/j.celrep.2018.07.009

708 25. Yates ME, Waltermire H, Mori K, et al. ESR1 Fusions Invoke Breast Cancer Subtype-
709 Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.
710 *Endocrinology*. 2024;165(10):bqae111. doi:10.1210/endocr/bqae111

711 26. Wang X, Zhou Y, Wu Z, et al. Single-cell transcriptomics reveals the role of antigen
712 presentation in liver metastatic breast cancer. *iScience*. 2024;27(2).
713 doi:10.1016/j.isci.2024.108896

714 27. Vallejo AF, Harvey K, Wang T, et al. snPATHO-seq: unlocking the FFPE archives for
715 single nucleus RNA profiling. Published online December 6, 2022:2022.08.23.505054.
716 doi:10.1101/2022.08.23.505054

717

718

719 **Supplemental 1:**

720 A copy of our SOP for autopsy collection.

1 **Figure 1: Study design and workflow of the HFO program**




2

3 Figure 1: Diagram illustrating the study design and workflow of the HfO Tissue Donation
4 Program.

5

**Figure 2: Summary figure of patient treatment timelines and clinical details**




Figure 2 – Mixture line and normalized timeline chart showing a summary of HfO program, including primary tumor molecular subtype, race, gender, histological subtype, stage at time of diagnosis (pathological if available, clinical if not), treatment markers and treatment categories up to August 2024.

**Figure 3: Examples of patient advocate media and figures demonstrating impact of key support staff.**




**Figure 3: a**. Promotion of tissue donation programs for advancing metastatic breast cancer (MBC) research via new media approaches such as podcasts and published media. Photos are of co-authors in this manuscript. **b**. Graph showing number of patients engaged at conferences/events. **c**. Bar plot shows the considerable standard deviation in mean transport time due to unique complexities within institutional and geographic contexts . **d**. Line graph shows the exponential increase in consent after an additional review of our operational protocols and rebranding (n = 114 consents, n = 34 autopsies [pre-2018 are not counted]). P-value from segmented regression 6.38E-31 for a change in consent rate slope post protocol review.

**Figure 4: Summary of collected samples, and statistics on tissue diversity and counts in autopsy and non-autopsy settings.**




Figure 4: **a**. Histogram that summarizes statistics for FFPE. Total of 1244, median of 41, range of 7 to 69. **b**. Histogram that summarizes statistics for frozen tumors. Total of 511, median of 12, range of 3-27. **c**. Histogram that summarizes statistics for cryovials from autopsy. Total of 1952, median of 46 per patient, range from 0 to 142. **d**. Histogram that summarizes our longitudinal blood collections. **e**. Segment pie charts using data from the US Aurora, EU Aurora, MET500, and HfO reports showing the distinctly different range of tissues collected in autopsy and non-autopsy settings.

**Figure 5: Diverse causes of death and subclinical metastases seen in autopsy settings, necessitating consistent collection.**




Figure 5: **a**. Bar plot showing the frequency of different causes of death in our program based on clinical note and autopsy report review (n = 37). **b**. Bar chart showing the mean increase in organs identified with metastases after careful pathological review on autopsy that were not identified in regular clinical monitoring, error bars are standard deviation. P-value 0.15 with paired t-test.. Images of **c**. ultrasound and **d**. MRI in a patient with ILC showing the CT-undetectable liver metastases. **e**. CT image and **f**. autopsy image at time of death for the patient with ILC illustrating the discrepancy between a 'normal' CT and the organ status. **g**. Scatter plot showing the difference in metastases seen clinically and in autopsy for patients with ILC. Patients with ILC have much more spread in peritoneal tissues that are undetectable clinically. **h**. Scatter bubble plot showing our FFPE collection, red box highlights our improved protocol to increase consistency in grossly normal tissues. Color corresponds to size of bubble. **i**. Figure showing our top 7 organ sites, collected whenever available, even if grossly normal under our new protocol.

**Figure 6: Single nuclei sequencing of paired frozen and fixed tissue samples.**




Figure 6: **a**. Side by side comparison of frozen vs fixed single nuclei sequencing data metrics shows significant improvement in fixed technologies with increase in genes detected, molecules detected, and less mitochondrial contamination. (n = 3) Run using 10x Genomics kit targeting 8000 cells. **b**. UMAP plot showing that frozen single nuclei sequencing lead to loss of signal causing failure of integration and removal of batch effects (n = 3), with diminished ESR1, and CD4 signal. **c**. Fixed single nuclei sequencing has better integration due to better signal recovery, with visible improvements in ESR1 and CD4 signal. PGR signal consistency across both sets shows that fixed technologies are not artificially introducing signal that isn't there. **d**. Bar plot showing the number of Hallmark pathways that have adjusted p-value less than 0.05 after pathway analysis between fixed and frozen cells, showing that fixed tissue almost always has better pathway signal. P-value calculated using chi-square test.

**Figure 7: Logistic regression results for PDO and PDX generation success.**




Figure 7: **a**. Logistic regressions for PDO attempts (n = 27 attempts) show that time to end of processing is predictive of success for PDO success. **b**. Logistic regressions for PDX attempts (n = 34 attempts) show that TNBC lesions are more likely to be successful. **c**. There are also significantly different probabilities of success on an intra-patient basis, implying that tissue of origin or tumor cellularity may play a role (n = 34). Work to establish relationships with organs of origin are ongoing.

**Figure 8: ESR1-ARNT2 fusion validation experiments.**




Figure 8: **a**. PDX model CTG-3533 shows stable growth. **b**. ER-immunoblot of TP18-M733 metastatic lesion protein samples. Red asterisks denote the expected size for the ESR1-ARNT2 fusion protein. $\beta$-actin serves as loading control in both blots, n=1. **c**, PDXO from CTG-3533 PDX can be cultivated from the PDX to extend back to in vitro experimentation. **d**. PDXO shows low levels of expression of the fusion construct and heterogenous signal. Sequencing also allows design of the fusion construct to be transfected into cells lines like T47D, as seen on ER-western blot. Red asterisks denote the expected size for the ESR1-ARNT2 fusion protein. $\beta$-actin serves as loading control in both blots, n=1.

93 **Figure S1: Histogram for time from consent to deaths per patient.**




94
95 **Figure S1**: Histogram summarizing our time from consent to death in months, rounded.
96

97

**Figure S2: Pathway scores comparison between fixed and frozen tissue.**

Figure S2. Downstream single cell analysis showing that fixed sequencing has better gene set percentage overlap and higher scores on average.

**Figure S3: Illustration of difference between chunked and minced tissue.**




Figure S3. Illustration of the difference between chunked and minced tissue.